Curevac appoints international financial expert michael brosnan to supervisory board

TÜbingen, germany and boston, ma / accesswire / june 20, 2023 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced the appointment of michael brosnan as an independent director to the company's supervisory board.
CVAC Ratings Summary
CVAC Quant Ranking